Shares of Eli Lilly & Co. LLY slipped 6.59% to $744.91 Tuesday, on what proved to be an all-around great trading session for ...

Palantir stock rebounds, sales of Eli Lilly’s blockbuster GLP-1 medicines miss estimates, and Boeing’s 2024 deliveries fall ...

though drops for Eli Lilly and other influential stocks kept indexes in check. The Standard & Poor's 500 rose 0.1% as three ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

2024 was an excellent year for the major stock market indexes. But the Dow Jones Industrial Average ( ^DJI 0.78%) had just a ...

Stocks were sharply lower Monday afternoon on concerns about the competitive threat that China poses in the race to develop artificial intelligence.

"Eli Lilly Cuts 4Q Sales Outlook After Sluggish Growth for Incretin Drugs," published at 10:06 a.m. ET, incorrectly said the outlook was around $400 below the low end of its last estimated range ...

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday ...

Drops for Eli Lilly and other influential companies are weighing on U.S. indexes Tuesday, even though most of the market is ...

Eli Lilly cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company sees healthy growth in 2025 due to the success ...

Eli Lilly's outlook for sales of its blockbuster ... following the December report on producer prices. The Dow Jones Industrial Average, S&P 500, and Nasdaq all were down less than 0.5%.

The Dow Jones Industrial Average rose on Tuesday as traders weighed ... they had for obesity drugs may not materialize as hoped. Lilly shares, which were approaching a trillion-dollar market ...